Given their roles in downstream signaling of cytokine receptors and growth factors, JAK/STAT pathways are considered as promising therapeutic targets for both cancer and autoimmune conditions.371 The efficacy of small-molecule JAK inhibitors in treating rheumatologic conditions illustrates the potential of targeting intracellular signaling pathways for autoimmune disease therapy.372. The gene discussed is SOAT1; the disease is cancer.